This study tests a new medicine called JCAR017 for adults with two types of blood cancer: Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). CLL and SLL are cancers where some of your white blood cells grow too much. If you join, you might get JCAR017 alone or with other medicines, like ibrutinib or venetoclax. The study has two parts: in the first part, doctors find the best dose of JCAR017. In the second part, they check how well it works and how safe it is. The study is open-label, which means you and the doctors know what treatment you are getting.

• The study involves taking JCAR017 with or without other medicines.
• It's important to meet certain health criteria before joining.
• You should discuss risks and benefits with your doctor before participating.

If you had other treatments that didn’t work, or you can’t use them, this study might be for you. Make sure you talk with your doctor to see if you qualify and if it’s a good fit for you. Remember, you can choose to leave the study at any time if you decide it’s not right for you.